2. シグナル伝達
  3. Immunology/Inflammation
  4. Cyclophilin
  5. Cyclophilin A Isoform

Cyclophilin A

 

Cyclophilin A 関連製品 (13):

製品番号 製品名 製品効果 純度
  • HY-107635
    TMN355 Inhibitor 99.67%
    TMN355 is a potent chemical cyclophilin A inhibitor and reduces foam cell formation and cytokine secretion. TMN355 is used for atherosclerosis.
  • HY-112712
    Cyclophilin inhibitor 1 Inhibitor 99.55%
    Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin A inhibitor, with a Kd of 5 nM, shows effective anti-HCV activity, with an EC50 of 98 nM for HCV 2a.
  • HY-135644
    Rencofilstat
    Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease.
  • HY-173011
    RJS308 Degrader 99.62%
    RJS308 is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 exhibits anti-HIV-1 and anti-HCV activities. RJS308 can be used in studies related to viral infections.
  • HY-124072
    HL001 Inhibitor 98.90%
    HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis.
  • HY-173012
    CypA ligand-2 Inhibitor
    CypA ligand-2 is the target protein ligand of PROTAC RJS308 (HY-173011). RJS308 is a PROTAC targeting CypA and exhibits antiviral activity.
  • HY-151488
    CypD-IN-4 Inhibitor
    CypD-IN-4 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-4 has CypD affinity with an IC50 value of 0.057 μM. CypD-IN-4 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes.
  • HY-151487
    CypD-IN-3 Inhibitor
    CypD-IN-3 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-3 has CypD affinity with an IC50 value of 0.01 μM. CypD-IN-3 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes.
  • HY-151489
    CypE-IN-1 Inhibitor
    CypE-IN-1 is a potent and subtype-selective cyclophilin E (CypE) inhibitor. CypE-IN-1 has CypE affinity with IC50 and Ki values of 0.013 μM and 0.072 μM, respectively. CypE-IN-1 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes.
  • HY-146648
    Cyclophilin inhibitor 3 Inhibitor
    Cyclophilin inhibitor 3 (compound 7c) is a potent cyclophilin A (CypA) inhibitor with an potent anti-HCV activity (EC50 of 4.2 μM).
  • HY-128924
    NIM258 Inhibitor
    NIM258 is a potent nonimmunosuppressive cyclophilin inhibitor (cyclophilin A Kd = 1.2 nM) with anti-HCV activity (EC50 = 40 nM). NIM258 can be used for HCV infection research.
  • HY-173009
    PROTAC CG167 Degrader
    PROTAC CG167 is a selective and potent CypA PROTAC degrader. PROTAC CG167 degrades CypA in a dose-dependent manner (Jurkat: DC50: 123 nM). PROTAC CG167 can inhibit HIV-1 and HCV and exhibits antiviral activity. (Pink: CypA Ligand (HY-170997); Black: Linker (HY-W123015); Blue: E3 Ligase Ligand (HY-112078))
  • HY-173013
    TWH106 Inhibitor
    TWH106 is an inhibitor for Cyclophilin (Cyp) that exhibits good affinity to CypA and CypB with KD of 53 nM and 139 nM. TWH106 inhibits the replication of HIV and HCV, exhibiting antiviral activity.